China's biopharmaceutical sector is experiencing increased investment, with funds from Singapore and the UAE supporting state-backed Chinese investors. Shanghai's Everest Medicines acquired rights to 14 chronic-disease treatments in the Asia-Pacific region.

China’s biopharmaceutical sector is seeing an uptick in deal-making, with sovereign wealth funds from Singapore and the United Arab Emirates joining Chinese state-backed investors to back next-generation drug developers. Shanghai-based Everest Medicines agreed to spend US$250 million to acquire a Singapore company holding rights to 14 chronic-disease treatments across the Asia-Pacific region, according to a stock exchange filing on Wednesday. Its Singapore unit will acquire 100 per cent of...